The company said it believes three doses 'may provide a higher level of protection in this age group.'
The move means that vaccines for this age group will not be available in the coming weeks, a setback for parents eager to vaccinate their young children.
The FDA was expected to publish an analysis of the Pfizer data Friday, ahead of an advisory committee meeting next week. The FDA said Friday the meeting has been postponed. However, Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said Friday that after regulators reviewed the company’s two-dose data, they decided they needed to see the three-dose data before considering authorization.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA postpones advisory panel meeting on Pfizer Covid-19 vaccine for younger childrenThe US Food and Drug Administration is postponing an advisory panel meeting on authorizing Pfizer’s Covid-19 vaccine in children under 5.
Weiterlesen »
Pfizer Postpones Request To Give COVID Vaccines To Kids Under 5The company said it will wait until it has more data on a third dose.
Weiterlesen »
US preps 10 million doses of COVID-19 vaccine for kids under 5, pending FDA authorizationCOVID-19 vaccines for kids under 5 have not yet been authorized, but the rollout plan is already in the works.
Weiterlesen »
Young kids’ COVID vaccines create approval dilemma for FDATwo doses of Pfizer's vaccine showed mixed results in trials, but the agency is considering approving it anyways in anticipation that a future third shot will provide children with strong immunity.
Weiterlesen »
Covid-19 vaccine authorization for younger children delayed as FDA postpones meetingThe US Food and Drug Administration is postponing an advisory panel meeting on authorizing Pfizer’s Covid-19 vaccine in children under 5.
Weiterlesen »